Skip to content

Treatment of melasma with topical unani medicine.

Therapeutic assessment of topical Husn-i-Yusuf with Rogan-i-Chambeli in managing Kalaf (melasma) - A randomized standard controlled trial. - NO

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/089523
Enrollment
40
Registered
2025-06-25
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: Husn-i-Yusuf with Rogan-i-Chambeli: Husn-i-yusuf will be finely ground and sieved to create a powder which will then be mixed with clarified Roghan-i-chambeli until a consistent paste

Sponsors

Luqmqn unani medical college hospital and research center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Both men and women are eligible Partipants aged between 18 to 50 years Individuals clinically diagnosed with melasma Participants able and willing to comprehend and adhere to the study protocol through out its duration

Exclusion criteria

Exclusion criteria: Pregnant or breast feeding women based on history Individuals with a history of current presence of skin allergies or allergic reactions to hydroquinone Individualss with a history of current presence of severe diseases including immunological conditions like HIV existing malignancies diabetes mellitus hypertension etc participants who have used any topical or systemic treatments for scalp conditions within 15 daysprior to the baseline assessment patients with a history of chemical peels and facial laser treatments within the past 9 months as well as those who have used sun protection creams

Design outcomes

Primary

MeasureTime frame
Change in Melasma Area and Severity Index mMASI scoreTimepoint: baseline 2nd 4th 6th and 8th weeks

Secondary

MeasureTime frame
Change in dermatology life quality index DLQI Timepoint: Baseline and after treatment;Change in IGA for melasma severity on 100mm VAS scoreTimepoint: Baseline and after treatment

Countries

India

Contacts

Public ContactDr saba mamdapur

Luqman unani medical college and research center

drdafedar1@gmail.com9032786832

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026